Amarin Co. plc Rating Reiterated by Aegis (AMRN)
Amarin Co. plc (NASDAQ:AMRN)‘s stock had its “buy” rating reiterated by Aegis in a research note issued on Friday, StockRatingsNetwork reports. They currently have a $30.00 price objective on the stock. Aegis’ price objective points to a potential upside of 354.55% from the stock’s previous close.
Amarin Co. plc (NASDAQ:AMRN) traded up 1.06% during mid-day trading on Friday, hitting $6.6701. The stock had a trading volume of 1,771,102 shares. Amarin Co. plc has a 52-week low of $5.12 and a 52-week high of $14.80. The stock’s 50-day moving average is $6.00 and its 200-day moving average is $6.70. The company’s market cap is $1.151 billion.
Amarin Co. plc (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. On average, analysts predict that Amarin Co. plc will post $-1.36 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at SunTrust initiated coverage on shares of Amarin Co. plc (NASDAQ:AMRN) in a research note to investors on Wednesday, September 4th. They set a “buy” rating on the stock. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Amarin Co. plc (NASDAQ:AMRN) in a research note to investors on Monday, August 12th. They now have a $11.00 price target on the stock, down previously from $13.00. Finally, analysts at MKM Partners cut their price target on shares of Amarin Co. plc (NASDAQ:AMRN) from $12.00 to $9.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock.
Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Amarin Co. plc currently has an average rating of “Buy” and a consensus target price of $13.63.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.